Study of TVAX-028 for chronic hepatitis B
Part of Infections clinical trials.
This trial tests a new study drug called TVAX-028, given along with your regular hepatitis B medicine, to see if it is safe and how well it works. It might help you control the virus better or even clear the surface antigen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have chronic hepatitis B, specifically HBeAg-negative (a type of hepatitis B).
- You must be on a stable antiviral medicine (like tenofovir or entecavir) with well-controlled HBV DNA.
- You must not have serious liver damage like cirrhosis or liver cancer.
- You cannot have other serious infections (HIV, hepatitis C, etc.) or uncontrolled health conditions.
- If you could become pregnant, you must agree to use effective contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational injection called TVAX-008 for people with chronic hepatitis B. It aims to see if the treatment can help clear the hepatitis B surface antigen, which may lead to a functional cure. The study is for people who have been on antiviral therapy and have well-controlled virus levels.
This study tests a two-step approach for chronic hepatitis B: first a shot called AHB-137, followed by another shot called TVAX-008. The goal is to see if this combination can help control the virus better.
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
Hear when a new HBV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.